Program
Actinium-225
Also written as “[225Ac]Ac-FL-261”, “[225Ac]Ac-AKY-2519 (therapeutic)” and “[225Ac]Ac-AKY-1189 (therapeutic)”.
Its studies are mostly in Prostatic Neoplasms · Triple Negative Breast Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Renal Cell, led by 6 companies.
Drug pageActinium-225: every studyMany companies study it; this page follows only the 10 they lead. All 13 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aktis Oncologyits history only | 33 open or running | phase 1since May 28, 2025 | May 28, 2025 | Dec 2027phase 1 · NCT07020117 |
| Alpha-9 Oncology USAits history only | 21 open or running | phase 1since Jun 27, 2025 | Jun 27, 2025 | Dec 2028phase 1 · NCT07661641 |
| AstraZenecaits history only | 21 open or running | phase 3since Apr 22, 2026 | Nov 9, 2018 | Jun 4, 2029phase 3 · NCT07611110 |
| Eli Lillyits history only | 11 open or running | phase 1since Jan 3, 2024 | Jan 3, 2024 | Sep 2027phase 1 · NCT06229366 |
| Full-Life Technologies UKits history only | 11 open or running | phase 2since Sep 23, 2026 | Sep 23, 2026 | Jun 30, 2030phase 2 · NCT07873450 |
| PeptiDreamits history only | 11 open or running | phase 1since Jun 17, 2026 | Jun 17, 2026 | May 2029phase 1 · NCT07688187 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 9, 2018First study: phase 1 study in Endometrial NeoplasmsNew to AstraZenecaAstraZeneca · NCT03746431 · 78 enrolled · United States, Australia, Canada
- Jan 3, 2024Eli Lilly’s first study: phase 1 study in Prostatic NeoplasmsNew to Eli LillyEli Lilly · NCT06229366 · 142 enrolled · Canada
- May 28, 2025Aktis Oncology’s first study: phase 1 study in Triple Negative Breast NeoplasmsNew to Aktis OncologyAktis Oncology · NCT07020117 · 150 planned · United States
- Jun 27, 2025Alpha-9 Oncology USA’s first study: phase 1 study in Uveal MelanomaNew to Alpha-9 Oncology USAAlpha-9 Oncology USA · NCT07076550 · 5 enrolled · Australia
- Apr 22, 2026Phase 3 study in Prostatic NeoplasmsPhase 3 reachedAstraZeneca · NCT07611110 · 670 planned · United States, Australia, Austria and more
- May 6, 2026Phase 1 study in Prostatic NeoplasmsAktis Oncology · NCT07581184 · 138 planned · United States
- Jun 9, 2026Phase 1 study in Breast NeoplasmsAlpha-9 Oncology USA · NCT07661641 · 115 planned · Australia
- Jun 17, 2026PeptiDream’s first study: phase 1 study in Carcinoma, Renal CellNew to PeptiDreamPeptiDream · NCT07688187 · 60 planned · United States
- Sep 23, 2026Full-Life Technologies UK’s first study: phase 2 study in Colorectal NeoplasmsNew to Full-Life Technologies UKFull-Life Technologies UK · NCT07873450 · 208 planned · United States, Australia, China
- Oct 15, 2026Phase 1 study in Carcinoma, Non-Small-Cell LungAktis Oncology · NCT07887971 · 152 planned · United States
Ahead
- Sep 2027Primary completion: phase 1 study in Prostatic NeoplasmsEli Lilly · NCT06229366
- Dec 2027Primary completion: phase 1 study in Prostatic NeoplasmsAktis Oncology · NCT07581184
- Dec 2027Primary completion: phase 1 study in Triple Negative Breast NeoplasmsAktis Oncology · NCT07020117
- Dec 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungAktis Oncology · NCT07887971
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07887971Carcinoma, Non-Small-Cell Lung · United States | 1 | Recruiting | Aktis Oncology | Dec 2028 | 152 |
| NCT07873450Colorectal Neoplasms · United States, Australia, China | 2 | Recruiting | Full-Life Technologies UK | Jun 30, 2030 | 208 |
| NCT07688187Carcinoma, Renal Cell · United States | 1 | Recruiting | PeptiDream | May 2029 | 60 |
| NCT07661641Breast Neoplasms · Australia | 1 | Recruiting | Alpha-9 Oncology USA | Dec 2028 | 115 |
| NCT07581184Prostatic Neoplasms · United States | 1 | Recruiting | Aktis Oncology | Dec 2027 | 138 |
| NCT07611110Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | AstraZeneca | Jun 4, 2029 | 670 |
| NCT07076550Uveal Melanoma · Australia | 1 | Terminated | Alpha-9 Oncology USA | Jul 9, 2026 | 5 |
| NCT07020117Triple Negative Breast Neoplasms · United States | 1 | Recruiting | Aktis Oncology | Dec 2027 | 150 |
| NCT06229366Prostatic Neoplasms · Canada | 1 | Active, not recruiting | Eli Lilly | Sep 2027 | 142 |
| NCT03746431Endometrial Neoplasms · United States, Australia, Canada | 1 | Terminated | AstraZeneca | Dec 3, 2025 | 78 |
How it is read
Names in the registry
- “[225Ac]Ac-FL-261”, 3 entries
- “[225Ac]Ac-AKY-2519 (therapeutic)”, 2 entries
- “[225Ac]Ac-AKY-1189 (therapeutic)”, 1 entry
- “Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])”, 1 entry
- “[Ac-225]-PSMA-62 (mCRPC)”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 3 studies
- Triple Negative Breast Neoplasms, 1 study
- Colorectal Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Carcinoma, Renal Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.